Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.

Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relap...

ver descrição completa

Detalhes bibliográficos
Autores: Gutierrez, A, Bento, L, Novelli, S, Martin, A, Gutierrez, G, Salas, MQ, Bastos-Oreiro, M, Perez, A, Hernani, R, Viguria, MC, Lopez-Godino, O, Montoro, J, Pinana, J, Ferra, C, Parody, R, Martin, C, Espanol, I, Yanez, L, Rodriguez, G, Zanabili, J, Herrera, P, Varela, M, Sampol, A, Solano, C, Caballero, D
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16722
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/16722
Access Level:acceso abierto
Palavra-chave:CAR-T cell therapy
acute graft-versus-host disease
allogeneic stem-cell transplantation
graft-versus-lymphoma effect
mantle cell lymphoma
non-relapse mortality
target therapy
id ES_06f67c04709fc5cf08d2e45fa6d68a4b
oai_identifier_str oai:incliva.fundanetsuite.com:p16722
network_acronym_str ES
network_name_str España
repository_id_str
spelling Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.Gutierrez, ABento, LNovelli, SMartin, AGutierrez, GSalas, MQBastos-Oreiro, MPerez, AHernani, RViguria, MCLopez-Godino, OMontoro, JPinana, JFerra, CParody, RMartin, CEspanol, IYanez, LRodriguez, GZanabili, JHerrera, PVarela, MSampol, ASolano, CCaballero, DCAR-T cell therapyacute graft-versus-host diseaseallogeneic stem-cell transplantationgraft-versus-lymphoma effectmantle cell lymphomanon-relapse mortalitytarget therapyAllo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/16722CancersISSN: 20726694reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p167222026-06-07T16:35:31Z
dc.title.none.fl_str_mv Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
title Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
spellingShingle Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
Gutierrez, A
CAR-T cell therapy
acute graft-versus-host disease
allogeneic stem-cell transplantation
graft-versus-lymphoma effect
mantle cell lymphoma
non-relapse mortality
target therapy
title_short Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
title_full Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
title_fullStr Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
title_full_unstemmed Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
title_sort Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.
dc.creator.none.fl_str_mv Gutierrez, A
Bento, L
Novelli, S
Martin, A
Gutierrez, G
Salas, MQ
Bastos-Oreiro, M
Perez, A
Hernani, R
Viguria, MC
Lopez-Godino, O
Montoro, J
Pinana, J
Ferra, C
Parody, R
Martin, C
Espanol, I
Yanez, L
Rodriguez, G
Zanabili, J
Herrera, P
Varela, M
Sampol, A
Solano, C
Caballero, D
author Gutierrez, A
author_facet Gutierrez, A
Bento, L
Novelli, S
Martin, A
Gutierrez, G
Salas, MQ
Bastos-Oreiro, M
Perez, A
Hernani, R
Viguria, MC
Lopez-Godino, O
Montoro, J
Pinana, J
Ferra, C
Parody, R
Martin, C
Espanol, I
Yanez, L
Rodriguez, G
Zanabili, J
Herrera, P
Varela, M
Sampol, A
Solano, C
Caballero, D
author_role author
author2 Bento, L
Novelli, S
Martin, A
Gutierrez, G
Salas, MQ
Bastos-Oreiro, M
Perez, A
Hernani, R
Viguria, MC
Lopez-Godino, O
Montoro, J
Pinana, J
Ferra, C
Parody, R
Martin, C
Espanol, I
Yanez, L
Rodriguez, G
Zanabili, J
Herrera, P
Varela, M
Sampol, A
Solano, C
Caballero, D
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CAR-T cell therapy
acute graft-versus-host disease
allogeneic stem-cell transplantation
graft-versus-lymphoma effect
mantle cell lymphoma
non-relapse mortality
target therapy
topic CAR-T cell therapy
acute graft-versus-host disease
allogeneic stem-cell transplantation
graft-versus-lymphoma effect
mantle cell lymphoma
non-relapse mortality
target therapy
description Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/16722
url https://incliva.portalinvestigacion.com/publicaciones/16722
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Cancers
ISSN: 20726694
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402950008307712
score 15,811543

Registos relacionados